Oculis Holding AG (OCS)

Oculis (NASDAQ:OCS) Hits New 1-Year Low – Should You Sell?

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS

Oculis Announces Resignation of Lionel Carnot from Board of Directors

Oculis Announces Resignation of Lionel Carnot from Board of Directors

After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)

UTStarcom Unveils Optical Circuit Switching (OCS) Solution for AI Data Centers at CIOE 2026

Analysts Set Oculis Holding AG (NASDAQ:OCS) Target Price at $39.44

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Reports Q2 2026 Financial Results and Provides Company Update

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses